The optimal sequence of pulmonary vessel interruption during lung cancer resection remains controversial. This review aimed to elucidate the association of vein-first versus artery-first ligation and survival of the patients.
Methods
We searched PubMed, Web of Science, Scopus, Embase, Cochrane Library and Google Scholar from their inception to September 2021 for published articles that compared vein-first (the pulmonary vein was interrupted first) and artery-first procedure (the pulmonary artery was ligated first) during lung cancer surgery.
Results
Finally, a total of 13 full articles were obtained. First, 7 studies with survival information were included for meta-analyses. As compared with the artery-first ligation, vein-first approach did not decrease the risk of local recurrence (risk ratio [RR] 0.92 in favour of vein-first; 95% confidence interval [CI] 0.61–1.39, p = 0.68) or distant metastasis (RR 0.92; 95% CI 0.30–2.85, p = 0.89); but it was associated with better disease-free survival (RR 0.52; 95% CI 0.37–0.73, p < 0.01) as well as 5-year overall survival (RR 0.60; 95% CI 0.41–0.86, p < 0.01). In addition, the operative time, intraoperative blood loss, total complications, and length of postoperative stay were mainly comparable between the two groups. Second, 7 studies provided the data of tumor cells indicated by different biomarkers and detection methods; and 3 of these reports showed that vein-first ligation decreased the extent of intraoperative tumor dissemination. However, a quantitative meta-analysis was not possible due to the significant heterogeneity.
Conclusion
Vein-first ligation in lung cancer surgery may be associated with improved survival of the patients, which might be ascribed to potentially lower risk of tumor cell dissemination. Well-designed, large-scale trials are warranted to clarify these occasional findings.
Hinweise
Tian Zhao and Chu Zhang contributed equally to this work
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
NSCLC
Non-small cell lung cancer
CTC
Circulating tumor cell
PA
Pulmonary artery
PV
Pulmonary vein
DFS
Disease-free survival
OS
Overall survival
CI
Confidence interval
RR
Risk ratio
RCTs
Randomized controlled trials
CEA
Carcinoembryonic antigen
Background
Surgical manipulation during lung cancer resection may dislodge circulating tumor cells (CTCs) into the effluent pulmonary vein (PV) [1]. In theory, blocking the PV of the tumor-bearing lobe first could decrease the risk and amount of iatrogenic tumor dissemination; however, the current studies have drawn controversial conclusions regarding the prognosis of non-small cell lung cancer (NSCLC) patients [2].
In 2015, a review of 7 studies showed that the ligation sequence of the pulmonary vessels did not influence the survival of lung cancer patients [3]. A propensity-score matched analysis in 2019 found that the NSCLC patients who underwent vein-first procedure demonstrated better survival compared to those in the artery-first group. In addition, the CTCs in peripheral blood were significantly decreased in vein-first patients than the control [4]. Nevertheless, vein-first ligation was correlated with better survival only in patients with stage I and II diseases [4]; whereas another study found that vein-first procedure only benefited stage I patients [5].
Anzeige
To the best of our knowledge, it is more convenient for the surgeons to ligate artery first in uniportal thoracoscopic lung resection; meanwhile, some surgeons advocate artery-first because it might decrease the amount of blood loss [6]. Herein an updated systemic review was conducted to qualitatively elucidate the role of vein-first versus artery-first interruption in lung cancer surgery.
Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used as reported [7]. This review was approved for publication by the Ethics Committee and Institutional Review Board of Xuzhou Central Hospital.
Literature search strategy
We searched PubMed, Web of Science, Scopus, Embase, Europe PMC, Cochrane Library and Google Scholar for studies up to September 2021 based on the population, intervention, comparator, outcome and strategy (PICOS) framework according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Protocol. Key words and MeSH terms in title or abstract including (1) “sequence” or “order” and (2) “ligation” or “sequence” or “interruption” or “resect*” or “dissect*” and (3) (“pulmonary” or “lung”) and (“vessel” or “vasculature” or “vein” or “artery”) and (4) “surgery” and “lung neoplasms/lung cancer” were used. The search strategy was as follows: ((ligation [Title/Abstract]) OR (interruption [Title/Abstract]) OR (resect* [Title/Abstract]) OR (dissect* [Title/Abstract])) AND ((pulmonary [Title] OR lung [Title] OR lobectomy [Title] OR (lung cancer surgery [Title])). No restriction was made regarding the publication language.
Selection criteria
The selection of studies was based on the titles, abstracts and full papers. Inclusion criteria were as follows: pathological diagnosis of lung cancer; comparative studies examining vein-first versus artery-first procedure during surgery; randomized controlled trials (RCTs), observational (retrospective/prospective cohort and case–control) studies; and studies that reported at least 1 outcome of interest such as the number of CTCs, the biomarkers (such as messenger ribonucleic acid [mRNA]) of tumor cells, postoperative local recurrence, distant metastasis, and survival. From the selected articles, the full texts were reviewed, followed by a decision on their eligibility for inclusion in a meta-analysis. Literature review, meta-analyses, letters to the editor, comments, correspondence, case reports, surgical technique notes, meeting abstracts, duplication publications or second analysis of the same database, unpublished studies, and single-arm reports (without control) were excluded.
Anzeige
Data collection
For each study, we identified the change of the biomarkers of CTCs or tumor cells in the PV and survival of the patients who underwent vein-first procedure (vein-first group) versus those who firstly ligated or resected the pulmonary artery (artery-first group) during lobectomy for cancer. The related studies were reviewed and the data were extracted by two researchers. Disagreements were resolved by consensus. Then these studies were exported to EndNote (Analytics, Philadelphia, PA, USA) for de-duplication [8].
The level of evidence was assessed by two independent reviewers and categorized per the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence [9]. The quality of evidence was graded by two authors independently. Disagreements were resolved by consensus. The primary endpoint was the change of CTCs or tumor cells or their biomarkers in the effluent PV; whereas the secondary endpoints were local recurrence, distant metastasis, disease-free survival (DFS), and overall survival (OS) of the patients after lobectomy with curative intent, respectively.
Statistical analysis
Risk ratio (RR) with 95% confidence intervals (CI) was calculated for categorical outcomes (local recurrence, distant metastasis, and mortality during the follow up). Study bias was detected using the methods of funnel plots test. Statistical significance was taken as 2-sided p value < 0.05. Meanwhile, the meta-analyses were performed with a random-effect model (rather than fixed-effect model). The meta-analyses were performed using RevMan software 5.3 (The Cochrane Collaboration, Copenhagen, Denmark).
Results
The initial search resulted in 22 studies. Finally, 13 full articles including 7 RCTs and 6 retrospective studies were included for review (Fig. 1). The sample sizes were mainly small (range from 11 to 210 patients in each report); therefore, the evidence level was mainly downgraded.
Fig. 1
Flow chart
×
The effect of vein-first ligation on survival of the patients
To date, 7 articles (2 RCTs and 5 observational studies) involving 1688 patients had been published, which investigated the role of vein-first procedure in the prognosis of the patients (Table 1) [4, 5, 10‐14].Vein-first ligation was performed on 869 patients, while the other 819 patients underwent artery-first surgery. Among them, 4 studies indicated that the interruption sequence of the vessels did not significantly affect the survival; whereas the other 3 studies demonstrated an obvious survival benefit for the patients in vein-first group.
Table 1
The oncological results in the 7 included studies (vein-first versus artery-first)
*According to the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence
The RCT by Kozak et al. randomized 385 NSCLC patients in the vein-first (n = 170) and artery-first group (n = 215) respectively [10], which demonstrated similar 5-year OS. Refaely et al. retrospectively reviewed 279 NSCLC patients, and both groups (133 cases in vein-first and 146 cases in artery-first) reported similar tumor recurrence [12]. Li et al. also reported similar OS; whereas artery-first procedure could reduce bleeding and postoperative complications [13]. Bai et al. found that vein-first vs. artery-first procedure did not affect the outcomes of early stage NSCLC patients in terms of local recurrence (6.7% vs 4.4%; p > 0.05) and distant metastasis (17.8% vs 13.3%; p > 0.05) [15].
On the contrary, a propensity-matched analysis showed that the vein-first patients demonstrated significantly better 5-year OS (73.6% vs 57.6%; p < 0.01), DFS (63.6% vs 48.4%; p < 0.01) and lung cancer-specific survival (76.4% vs 59.9%; p < 0.01) than the control [4]. In addition, a retrospective study showed that the DFS of the patients in vein-first and non-vein-first groups was 6.7% (7/104) and 18.1% (15/83), respectively (p < 0.05) [5]. Moreover, a retrospective study of 60 NSCLC patients (33 in vein-first and 27 in artery-first group) reported similar OS (p > 0.05); however, subgroup analysis revealed that vein-first procedure delivered better survival in squamous cell carcinoma patients [14].
Furthermore, Wei et al. reported that vein-first procedure was correlated with better survival in stage I and stage II patients but not stage III cases [4]. Sumitomo et al. also indicated that vein-first ligation provided better survival for the patients in stage I but not stage II or IIIA diseases [5].
Anzeige
In addition, the perioperative characteristics of the patients (vein-first versus artery-first) were shown in Table 2. Because only 2 RCTs with quite limited sample have been reported to date, we only used Level of Evidence instead of risk of bias to classify the studies. Operative time, intraoperative blood loss, total complications, and postoperative hospital stay were mainly comparable between the two groups.
Table 2
Perioperative characteristics of the patients (vein-first versus artery-first)
Only 7 reports in Table 3 were possible for meta-analyses. The forest plots for the comparisons of local recurrence, distant metastasis, DFS and OS between the groups were generated respectively (Fig. 2).
Table 3
The change of tumor cells in the effluent pulmonary veins after lobectomy (vein-first versus artery-first)
Serum cytokeratin 19 (CK19)/adhesion molecule CD44v6 mRNA was changed significantly after surgery in artery-first group, but not vein-first group, p < 0.05
*According to the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence
Fig. 2
Forest plots for the comparisons of oncological outcomes. A Local recurrence; B distant metastasis; C disease-free survival; D overall survival
×
For the 4 reports with a local recurrence rate, the heterogeneity was as follows: I2 = 0%. No significant difference in terms of local recurrence was noted (RR 0.92 in favour of vein-first ligation; 95% confidence interval [CI] 0.61–1.39, p = 0.68). Moreover, for the 3 reports with distant metastasis data, the heterogeneity was as follows: I2 = 67%. No significant difference regarding distant metastasis was observed between the two groups (RR 0.92 in favour of vein-first ligation; 95% CI 0.30–2.85, p = 0.89).
Three reports presented detailed DFS information, and the heterogeneity was as follows: I2 = 40%. Vein-first group demonstrated lower risk of mortality compared to the control (RR 0.52 in favour of vein-first ligation; 95% CI 0.37–0.73, p < 0.001). Similarly, for the 4 reports with OS data, the heterogeneity was as follows: I2 = 63%. Vein-first group demonstrated significantly better 5-year overall survival compared to the counterpart (RR 0.60; 95% CI 0.41–0.86, p = 0.005).
Anzeige
Sensitivity analysis
We combined different study types in the above meta-analyses. Thus, a sensitivity analysis was conducted. Actually, the available data, especially prospective studies regarding DFS and OS, are quite limited to provide an adequately powered meta-analysis. Thus, a sensitivity analysis is not significantly helpful to strengthen the quality of this meta-analysis. When the 2 RCTs were excluded from the meta-analysis one by one (Kozak, 2013; Bai, 2016) [10, 11], the results in favor of vine-first resection were not changed. In detail, both groups showed similar local recurrence and distant metastasis rate (p > 0.05, respectively); whereas the vein-first patients demonstrated better 5-year OS compared to artery-first group (RR 0.61; 95% CI 0.48–0.77, p < 0.001). Furthermore, the funnel plot in the meta-analysis suggested publication bias (Fig. 3).
Fig. 3
Funnel plot of publication biases of the 7 studies in the meta-analyses
×
The effect of vein-first ligation on CTCs
Seven studies presented the change of tumor cells in the effluent PV after lung cancer surgery (Table 3), including 5 RCTs and 2 observational studies [1, 4, 15‐19]. Three of them indicated that vein-first ligation was associated with a lower risk of intraoperative tumor dissemination; whereas the others recorded similar outcomes. However, a quantitative meta-analysis regarding CTCs was not possible because these studies used different tumor biomarkers and calculation methods.
A multicenter RCT (NCT03436329) showed an incremental change of CTCs in 26 of 40 patients (65.0%) in the artery-first group and 12 of 38 (31.6%) in the vein-first group (p < 0.01) after surgery for NSCLC [4]. Kurusu et al. examined the presence of CTCs as reflected by carcinoembryonic antigen (CEA) mRNA in 30 NSCLC patients [15]. Of the 14 initially negative samples (7 in each group), 9 samples became positive during the operation, and such conversion was more common with artery-first (6 patients, 85.7%) than vein-first procedure (3 patients, 42.9%). In addition, exploiting cytokeratin 19 and CEA mRNA as markers of malignant cells, Ge et al. collected 23 NSCLC patients [16], which showed that vein-first procedure may partly prevent release of tumor cells into bloodstream. Moreover, Song et al. randomized NSCLC patients into artery-first and vein-first group (15 cases in each) [18]. The expression of cytokeratin 19 and adhesion molecule CD44v6 mRNA as biomarkers of lung cancer micrometastasis in the late period of surgery were higher than those in the early period in artery-first group (p < 0.05); whereas neither the cytokeratin 19 nor CD44v6 after surgery in the vein-first group exhibited significant change versus those before surgery (p > 0.05). The authors therefore concluded that vein-first ligation help lower the risk of manipulation-related micrometastasis. Similarly, a prospective study of 33 patients showed that the number of CTCs was 3.36 before PV interruption; whereas it increased to be 14.88 after lobectomy for lung cancer [1]. Therefore, surgical manipulation may dislodge tumor cells into the PV but vein-first procedure may decrease the CTCs entry into the circulation.
On the other hand, Hashimoto et al. reported that the increase of CTCs in the PV was not significantly associated the sequence of vessel interruption [19].
Anzeige
Discussion
The present meta-analyses including 7 studies published from 1998 to 2021 tried to compare the survival using RR because only 2 hazard ratios was available. In the study, no difference between the vein-first and artery-first groups was indicated in terms of postoperative recurrence and distant metastasis, but the patients underwent vein-first ligation procedure showed obviously lower 5-year overall mortality as compared to the control group. We provide updated evidence supporting vein-first surgery for improved survival. In theory, the potentially improved prognosis might be ascribed to lower surgery-related tumor cell dissemination. Nevertheless, the current studies regarding the risk of CTCs dissemination is still insufficient for meta-analysis.
Only a review has so far been published [3]. Toufektzian et al. qualitatively summarized the results of 6 prospective and 1 retrospective studies; and thy found that the sequence of pulmonary vessels ligation did not seem to influence the oncological outcomes of lung cancer patients. Our study included several newly presented reports, and conducted the first meta-analysis of survival associated with the sequence of vessels ligation in lung cancer surgery. Due to publication bias, small samples, heterogeneity and the inherent limitations of meta-analysis involving observational studies, our findings should be interpreted with caution.
The increase of CTCs after surgical manipulation might explain the distant metastases after tumor resection [20]. The detection methods of CTCs and the type of mRNA were inconsistent in the present review; therefore, standardized criteria for the collection of blood samples and detection of the CTCs as well as the tumor cells in PV should be considered in further trials. Moreover, surgeons’ experience was correlated with the operation time before PV interruption, which might explain the distinct prognosis of lung cancer patients treated by different surgeons [21]. As a result, it is probably indisputable that oncological surgery should be performed by experienced surgeons to avoid excessive manipulation of the tumor-bearing lobe before the interruption of the effluent PV.
Similarly, the operation time before PV ligation (later or earlier than artery interruption) may affect the quantity of tumor cells released into the circulation. However, to date we find only 1 registered trial (ChiCTR1800016879) evaluating the effect of different timing before PV ligation on the prognosis of the lung cancer patients. The registered trials comparing vein-first and artery-first ligation in lung cancer surgery were listed in Table 4. A definite conclusion might be drawn from the forthcoming researches.
Table 4
The registered trials of vein-first versus artery-first ligation in lung cancer surgery
Identifier
Year
Neoadjuvant chemotherapy or radiotherapy
Staging
Surgical procedure
Study design
Estimated enrollment
Major outcomes
Status
Country
NCT00341380
2006
Not mentioned
Stage I ~ II
Resection of non-small cell lung tumor
Prospective cohort study
41
Postoperative metastases/recurrence
Completed
America
NCT03645252 (CTC-01)
2018
None
cT1 ~ 3N0M0
Lobectomy/bi-lobectomy
Randomized pilot study
30
The change of CTC in pulmonary vein; DFS; OS
Not yet recruiting
Canada
NCT03436329
2018
None
Stage I–IV eligible for surgery
Lobectomy
Multi-centre randomized controlled trial
60
CTC level before cutting the skin and after closing the chest; 3-year PFS; complications
Moreover, the disadvantages of vein-first lung resection should not be neglected. Vein-first procedure was reported to be associated with more intraoperative blood loss as compared with artery-first surgeries [13]. It might be difficult to separate the PV first before the removal of calcified lymph nodes around the PV. Moreover, not all the branches of the PV with anatomic variants could be interrupted simultaneously and quickly before artery ligation. Considering the safety of the patients, artery-first or mixed procedure, instead of vein-first ligation, might be the optimal choice when the PV is deeply located.
The available data of perioperative complications were listed in Table 2, which showed that the operative time, intraoperative estimated blood loss, total complications, and length of postoperative stay were mainly comparable between the two groups. Detailed information of the events is not available and truly limited, so additional meta-analyses are not possible. Further trials are necessary to clarify the actual role of vein-first ligation in surgery-related complications such as bleeding and conversion to open thoracotomy during thoracoscopic lung cancer surgery. Because only 2 RCTs regarding oncological results with quite limited samples have been reported to date, we only used Level of Evidence, instead of Cochrane risk-of-bias tool, to classify the quality of the retrieved studies.
Lastly, we acknowledge several significant limitations to this review. First, 5 of the 7 reports in the meta-analyses indicated low quality of evidence and great risk of bias due to small samples and retrospective nature. The articles of different study types (RCTs and non-RCT reports) were pooled both together and separately for sensitivity analysis. The estimates from observational studies might be overestimated due to selection bias, which might result in misleading information. Meanwhile, the potential items correlated with survival of the patients including but not limited to neoadjuvant treatment, the operation time before PV interruption, the stations and total number of dissected lymph nodes, and postoperative multimodal therapeutic regimens, which were not reported in detail in most of the studies. Second, different surgical preference, experience, and learning curve of clinicians might also affect the outcomes. Third, unpublished data and relevant articles in non-English and non-Chinese databases may be neglected. Furthermore, the detailed information of perioperative complications and quality of life are not definitely available from the retrieved studies. Further well-designed trials are warranted to clarify the role of vein-first procedure in manipulation-related complications including bleeding and conversion to open surgery during lung cancer surgery. In addition, the following issues such as open vs. minimal-invasive surgery, extent of surgery (lobectomy vs. pneumonectomy vs. segmentectomy), length-of-stay in hospital and intensive care unit (ICU), perioperative chemotherapy and immunotherapy, type and stage of cancer should also be incorporated and compared to further define the definite role of vein-first procedure in lung cancer resection. Thus, the actual benefit of vein-first ligation for patients undergoing lung cancer surgery largely remains unanswered.
Conclusions
Vein-first ligation in lung cancer surgery may be associated with improved prognosis and potentially decreased risk of manipulation-related tumor dissemination. Well-designed, large-scale trials are warranted to verify these findings before a definite recommendation could be drawn.
Acknowledgements
The authors will thank the statisticians in Xuzhou Central Hospital for their great help in data preparation and analysis. Meanwhile, the authors would like to thank all the reviewers for their constructive advices.
Declarations
Ethics approval and consent to participate
This review was approved by the Ethic Committee of Xuzhou Central Hospital.
Consent for publication
Written informed consent for publication was obtained from all participants.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.
Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.
Update Chirurgie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
